

Effectiveness of various Vitamin D protocols on raising and maintaining blood serum 25(OH)D3 levels over a three month period

Perry Hooper, DO

Cesar Cereijo DO; Rikesh Patel DO; Timothy Wagner MD

Principal Investigator: Damien Billow MD

Department of Orthopaedic Surgery

South Pointe Hospital

Cleveland Clinic Foundation

Introduction

- Rise in interest regarding the health benefits of Vitamin D supplementation
- Increased appreciation of Vitamin D and its importance in musculoskeletal health and other medical conditions
- Primary role of Vitamin D is to maintain serum calcium homeostasis



Introduction

- Vitamin D sufficiency is estimated by measuring serum 25-hydroxyvitamin D (25[OH]D) and optimal serum concentrations are controversial
- National Osteoporosis Foundation (NOF) and American Geriatric Society (AGS) recommend minimum of 30ng/ml
- No clear consensus on optimal Vitamin D dosing



Methods

- Randomized, prospective study to evaluate three vitamin D dosing regimens and their effect on serum 25 OH-D over a span of three months
- Funding provided by Brentwood Foundation
- Subjects were then assigned one of three dosing regimens:
 - **Group 1: 100,000U IU Vit D2 once**
 - **Group 2: 100,000U IU Vit D2 once weekly x 12 weeks**
 - **Group 3: 50,000U IU Vit D2 daily x 10 days then 2000U Vit D3 daily**
- Lab Draws (Serum 25OH-D): 0,2,6, and 12 Weeks

Methods

- Single hospital system
- Voluntarily enrolled subjects
- **Inclusion Criteria:**
 - Male or Female, 18 years of age or older
- **Exclusion Criteria:**
 - Pregnant
 - PMHx: endocrinopathies, granulomatous disorders, active cancer or any other vitamin d altering medical conditions
 - Patient taking any medication which interferes with Vitamin D absorption and metabolism including: Steroids (Prednisone), Orlistat (Xenical & Alli), Cholestyramine (Questran, LoCholest, Prevalite), Dilantin (Phenytoin), Phenobarbital, and any anti-tuberculosis drugs
 - Patient taking any medication which may increase Vitamin D levels such as cholesterol-lowering statin drugs and thiazide diuretics.
 - Initial Vitamin D levels over 30 ng/ml

Methods

- Participants were randomized into each of the 3 groups using an algorithm created on Redcap Database
- **Statistics:**
 - It was determined by our research statistician for a standardized effect size of 0.5 units, which may generally be considered clinically important between placebo and any other dose regimen, and a **power of 95%, a total of 45 subjects (15 subjects per episode) would be required to achieve statistical significance** among the three groups, using repeated measures ANOVA over 4 time points
 - Alpha was set at 0.05
 - Assuming that up to 5 subjects per group would be lost to follow-up; leaving 30 subjects in the study (10 per group), a reasonable power of 80% would still be achieved



Methods

- Study participants were given:
 - Dosing log
 - Side effects log
 - Post-study questionnaire
- Participants were monitored by research coordinator via phone throughout study
- If supra-therapeutic vit D blood levels were noted on lab draws participants were contacted to check for symptoms



Methods

Initial screening questionnaire for study eligibility

Total Participants Enrolled: 86

- 14 withdrew or cancelled after enrollment
 - 8 cancelled
 - 6 withdrew mid study

Total Participants that met inclusion/exclusion criteria: 72

- 32% (24) of participants excluded due to normal Vit D value on initial draw
 - Excluded from June-Sept: 63% (17 of 27)
 - Excluded from Oct-Mar: 27% (6 of 22)
- 1 participant was excluded due to missed doses during the study

Total Participants Included in Vitamin D study: 48

- Group 1 participants: 15
- Group 2 participants: 16
- Group 3 participants: 17



Methods

• Beneficial Side Effects

- Improved mood
- Improved energy
- Decrease chronic pain
- Improved musculoskeletal strength
- Improved immune function and overall health



Methods

Vitamin D Toxicity - symptoms of acute intoxication are generally associated with hypercalcemia and can ultimately lead to renal damage and tissue calcifications

<u>Mild Symptoms</u>	<u>Severe Symptoms</u>
Fatigue	Confusion
Constipation	Polyuria
Irritability	Polydipsia
Insomnia	Anorexia
Nervousness	Nausea
Pruritis	Vomiting
	Muscle Weakness

Results

Factor	Total	Treatment Group 1		Treatment Group 2		Treatment Group 3		p-value
		N	Statistics	N	Statistics	N	Statistics	
Vitamin D Blood Level at Week 0 ^a	48	15	22.28 ± 4.73	16	22.92 ± 5.17	17	19.86 ± 5.02	0.19 ^A
Vitamin D Blood Level at Week 2 (14 ± 4 days) ^a	48	15	28.5 ± 7.65	16	43.52 ± 13.5	17	61.24 ± 18.08	< 0.001 ^A
Vitamin D Blood Level at Week 6 (43 ± 3 days) ^a	48	15	22.85 ± 6.22	16	57.06 ± 20.06	17	44.71 ± 14.2	< 0.001 ^A
Vitamin D Blood Level at Week 12 (84 ± 5 days) ^a	48	15	19.46 ± 5.61	16	59.13 ± 20.73	17	36.94 ± 14	< 0.001 ^A

^a Mean ± SD

A: Analysis of Variance


Results

Total Change in Vitamin D level throughout twelve week period per group

	Total Change 25(OH)D3	Standard Deviation
Group 1	-2.820	3.050
Group 2	36.212	2.953
Group 3	17.071	2.86

Results

Group 1 per Blood Draw




		P-value
Group 1	Week 0 - Week 2	0.178
	Week 0 - Week 6	0.998
	Week 0 - Week 12	0.792

Results

Treatment Group	Contrast	Estimate	Std. Error	95% CI on Estimate	P-value
Group 1	Week 0 - Week 2	-6.220	3.050	-14.15 -- 1.71	0.178
	Week 0 - Week 6	-0.567	3.050	-8.49 -- 7.36	0.998
	Week 0 - Week 12	2.820	3.050	-5.11 -- 10.75	0.792
	Week 2 - Week 6	5.653	3.050	-2.27 -- 13.58	0.253
	Week 2 - Week 12	9.040	3.050	1.11 -- 16.97	0.018
	Week 6 - Week 12	3.387	3.050	-4.54 -- 11.31	0.684

Results

Group 2 per Blood Draw




		P-value
Group 2	Week 0 - Week 2	<0.001
	Week 0 - Week 6	<0.001
	Week 0 - Week 12	<0.001

Results

Treatment Group	Contrast	Estimate	Std. Error	95% CI on Estimate	P-value
Group 2	Week 0 - Week 2	-20.606	2.953	-28.28 -- -12.93	<0.001
	Week 0 - Week 6	-34.144	2.953	-41.82 -- -26.47	<0.001
	Week 0 - Week 12	-36.212	2.953	-43.89 -- -28.54	<0.001
	Week 2 - Week 6	-13.537	2.953	-21.21 -- -5.86	<0.001
	Week 2 - Week 12	-15.606	2.953	-23.28 -- -7.93	<0.001
	Week 6 - Week 12	-2.069	2.953	-9.74 -- 5.61	0.897

Results

Group 3 per Blood Draw



		P-value
Group 3	Week 0 - Week 2	<0.001
	Week 0 - Week 6	<0.001
	Week 0 - Week 12	<0.001




Results

Treatment Group	Contrast	Estimate	Std. Error	95% CI on Estimate	P-value
Group 3	Week 0 - Week 2	-41.371	2.865	-48.82 -- -33.92	<0.001
	Week 0 - Week 6	-24.841	2.865	-32.29 -- -17.40	<0.001
	Week 0 - Week 12	-17.071	2.865	-24.52 -- -9.62	<0.001
	Week 2 - Week 6	16.529	2.865	9.08 -- 23.98	<0.001
	Week 2 - Week 12	24.300	2.865	16.85 -- 31.75	<0.001
	Week 6 - Week 12	7.771	2.865	0.32 -- 15.22	0.037


Results

	P-value
Vitamin D Blood Level at Week 0	0.19 ^A
Vitamin D Blood Level at Week 2	< 0.001 ^A
Vitamin D Blood Level at Week 6	< 0.001 ^A
Vitamin D Blood Level at Week 12	< 0.001 ^A



Results

Comparison of Group Progressions through 12 week period



Results

Treatment Group	Contrast	Estimate	Std. Error	95% CI on Estimate	P-value
Week 0	Group 1 - Group 2	-0.639	4.472	-11.28 -- 10.00	0.989
	Group 1 - Group 3	2.415	4.408	-8.07 -- 12.90	0.848
	Group 2 - Group 3	3.054	4.334	-7.26 -- 13.36	0.761
Week 2	Group 1 - Group 2	-15.025	4.472	-25.66 -- -4.39	0.003
	Group 1 - Group 3	-32.735	4.408	-43.22 -- -22.25	<0.001
	Group 2 - Group 3	-17.710	4.334	-28.02 -- -7.40	<0.001
Week 6	Group 1 - Group 2	-34.216	4.472	-44.85 -- -23.58	<0.001
	Group 1 - Group 3	-21.859	4.408	-32.34 -- -11.37	<0.001
	Group 2 - Group 3	12.357	4.334	2.05 -- 22.67	0.014
Week 12	Group 1 - Group 2	-39.671	4.472	-50.31 -- -29.03	<0.001
	Group 1 - Group 3	-17.475	4.408	-27.96 -- -6.99	<0.001
	Group 2 - Group 3	22.196	4.334	11.89 -- 32.51	<0.001

Results

Post-study Questionnaire: Positive Side Effects

	Group 1		Group 2		Group 3		Total		P-value
	Yes	No	Yes	No	Yes	No	Yes	No	
Happier?	40%	60%	31.25%	68.75%	58.83%	41.18%	43.75%	56.25%	0.28
Stronger?	13.33%	86.67%	37.25%	62.5%	47.06%	52.94%	33.33%	66.67%	0.13
Better or Healthier?	26.67%	73.33%	43.75%	56.25%	58.82%	41.18%	43.75%	56.25%	0.21
Less Pain?	26.67%	73.33%	31.25%	68.75%	23.53%	76.47%	27.08%	72.92%	0.92
More Energy?	20.00%	80.00%	56.25%	43.75%	41.18%	58.82%	39.58%	60.42%	0.14
Will you continue taking Vitamin D supplements?	80.00%	20.00%	81.25%	18.75%	82.35%	17.65%	81.25%	18.75%	>0.99

Results

Negative Side Effects Documented by Participants

	Group 1		Group 2		Group 3		Total		P-value
	Yes	No	Yes	No	Yes	No	Yes	No	
Negative Side Effects	0.00%	100%	12.5%	87.5%	17.65%	82.35%	10.42%	89.58%	0.35
Side Effects Documented	None		<u>2 out of 16</u> - Occasional headaches (prior hx of migraines) - Occasional joint and muscle pain		<u>3 out of 17</u> - Fatigue - Headache - Constipation				

Conclusions

- **Group 1: 100,000U IU Vit D2 once**
 - Group 1 did not have any significant statistical increase at any time point
- **Group 2: 100,000U IU Vit D2 once weekly x 12 weeks**
 - Group 2 showed a sustained and **overall largest increase** in Vit D levels over the twelve week period
 - Significantly higher at **week 6 and 12** compared to other groups
- **Group 3: 50,000U IU Vit D2 daily x 10 days then 2000U Vit D3 daily**
 - Group 3 showed highest increase in Vit D levels at **week 2**



Limitations

- Single center
- Study performed over 12 week time period



Conclusion

- Large dosing regimens higher than previously studied protocols show safe to be given with **zero severe adverse effects**
- Not only is supplementation safe but shown to be beneficial
 - **25-45%** of all participants stated they had positive effects
 - Some participants noted **>50% positive effects** on health
- **82.15%** of all participants stated they will continue taking vitamin D supplementation post study

Recommendations

- 100,000 IU Vitamin D2 weekly
- No baseline screening needed
 - 68% of healthy volunteers had low vit D
 - Dosing regimens shown to be safe with zero severe negative side effects and infrequent minor side effects

Future Applications

- Efficacy of Vitamin D supplementation on fracture healing
- Apply group 2 regimen to fractures in prospective multicenter study to compare non-union rates



References

1. John S. Davies, Chris D. Poole & Peter Feldschreiber. "The medico-legal aspects of prescribing Vitamin D." *British Journal of Clinical Pharmacology* (2014): 78(6):1257-1263.
2. Patton CM, Powell AP, Patel AA. "Vitamin D in Orthopedics." *The Journal of the American Academy of Orthopedic Surgeons* (2012 Mar): 20(3):123-9.
3. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK56070/> doi: 10.17226/13050
4. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997; 337:670.
5. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study. *Osteoporos Int* 2002; 13:257.
6. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003; 326:469.
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96:1911.
8. Vieth R. What is the optimal vitamin D status for health? *Prog Biophys Mol Biol* 2006; 92:26.
9. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. *Osteoporos Int* 2010; 21:1151.
10. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. *J Am Geriatr Soc* 2014; 62:147.

Thank You



Cleveland Clinic
Department of Orthopaedic Surgery